Cargando…
Mesenchymal Stromal Cell-Based Therapy: New Perspectives and Challenges
Stem cells have been the focus of intense research opening up new possibilities for the treatment of various diseases. Mesenchymal stromal cells (MSCs) are multipotent cells with relevant immunomodulatory properties and are thus considered as a promising new strategy for immune disease management. T...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572531/ https://www.ncbi.nlm.nih.gov/pubmed/31071990 http://dx.doi.org/10.3390/jcm8050626 |
_version_ | 1783427662306344960 |
---|---|
author | Najar, Mehdi Bouhtit, Fatima Melki, Rahma Afif, Hassan Hamal, Abdellah Fahmi, Hassan Merimi, Makram Lagneaux, Laurence |
author_facet | Najar, Mehdi Bouhtit, Fatima Melki, Rahma Afif, Hassan Hamal, Abdellah Fahmi, Hassan Merimi, Makram Lagneaux, Laurence |
author_sort | Najar, Mehdi |
collection | PubMed |
description | Stem cells have been the focus of intense research opening up new possibilities for the treatment of various diseases. Mesenchymal stromal cells (MSCs) are multipotent cells with relevant immunomodulatory properties and are thus considered as a promising new strategy for immune disease management. To enhance their efficiency, several issues related to both MSC biology and functions are needed to be identified and, most importantly, well clarified. The sources from which MSCs are isolated are diverse and might affect their properties. Both clinicians and scientists need to handle a phenotypic-characterized population of MSCs, particularly regarding their immunological profile. Moreover, it is now recognized that the tissue-reparative effects of MSCs are based on their immunomodulatory functions that are activated following a priming/licensing step. Thus, finding the best ways to pre-conditionate MSCs before their injection will strengthen their activity potential. Finally, soluble elements derived from MSC-secretome, including extracellular vesicles (EVs), have been proposed as a cell-free alternative tool for therapeutic medicine. Collectively, these features have to be considered and developed to ensure the efficiency and safety of MSC-based therapy. By participating to this Special Issue “Mesenchymal Stem/Stromal Cells in Immunity and Disease”, your valuable contribution will certainly enrich the content and discussion related to the thematic of MSCs. |
format | Online Article Text |
id | pubmed-6572531 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-65725312019-06-18 Mesenchymal Stromal Cell-Based Therapy: New Perspectives and Challenges Najar, Mehdi Bouhtit, Fatima Melki, Rahma Afif, Hassan Hamal, Abdellah Fahmi, Hassan Merimi, Makram Lagneaux, Laurence J Clin Med Editorial Stem cells have been the focus of intense research opening up new possibilities for the treatment of various diseases. Mesenchymal stromal cells (MSCs) are multipotent cells with relevant immunomodulatory properties and are thus considered as a promising new strategy for immune disease management. To enhance their efficiency, several issues related to both MSC biology and functions are needed to be identified and, most importantly, well clarified. The sources from which MSCs are isolated are diverse and might affect their properties. Both clinicians and scientists need to handle a phenotypic-characterized population of MSCs, particularly regarding their immunological profile. Moreover, it is now recognized that the tissue-reparative effects of MSCs are based on their immunomodulatory functions that are activated following a priming/licensing step. Thus, finding the best ways to pre-conditionate MSCs before their injection will strengthen their activity potential. Finally, soluble elements derived from MSC-secretome, including extracellular vesicles (EVs), have been proposed as a cell-free alternative tool for therapeutic medicine. Collectively, these features have to be considered and developed to ensure the efficiency and safety of MSC-based therapy. By participating to this Special Issue “Mesenchymal Stem/Stromal Cells in Immunity and Disease”, your valuable contribution will certainly enrich the content and discussion related to the thematic of MSCs. MDPI 2019-05-08 /pmc/articles/PMC6572531/ /pubmed/31071990 http://dx.doi.org/10.3390/jcm8050626 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Editorial Najar, Mehdi Bouhtit, Fatima Melki, Rahma Afif, Hassan Hamal, Abdellah Fahmi, Hassan Merimi, Makram Lagneaux, Laurence Mesenchymal Stromal Cell-Based Therapy: New Perspectives and Challenges |
title | Mesenchymal Stromal Cell-Based Therapy: New Perspectives and Challenges |
title_full | Mesenchymal Stromal Cell-Based Therapy: New Perspectives and Challenges |
title_fullStr | Mesenchymal Stromal Cell-Based Therapy: New Perspectives and Challenges |
title_full_unstemmed | Mesenchymal Stromal Cell-Based Therapy: New Perspectives and Challenges |
title_short | Mesenchymal Stromal Cell-Based Therapy: New Perspectives and Challenges |
title_sort | mesenchymal stromal cell-based therapy: new perspectives and challenges |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572531/ https://www.ncbi.nlm.nih.gov/pubmed/31071990 http://dx.doi.org/10.3390/jcm8050626 |
work_keys_str_mv | AT najarmehdi mesenchymalstromalcellbasedtherapynewperspectivesandchallenges AT bouhtitfatima mesenchymalstromalcellbasedtherapynewperspectivesandchallenges AT melkirahma mesenchymalstromalcellbasedtherapynewperspectivesandchallenges AT afifhassan mesenchymalstromalcellbasedtherapynewperspectivesandchallenges AT hamalabdellah mesenchymalstromalcellbasedtherapynewperspectivesandchallenges AT fahmihassan mesenchymalstromalcellbasedtherapynewperspectivesandchallenges AT merimimakram mesenchymalstromalcellbasedtherapynewperspectivesandchallenges AT lagneauxlaurence mesenchymalstromalcellbasedtherapynewperspectivesandchallenges |